Skip to content
Calculator
Evidence: LowPeptideResearch ChemicalDipeptide (Lys-Glu)Not approved anywhereMostly animal and cell studies

Vilon

A two-amino-acid Khavinson peptide called a thymomimetic

Vilon is lysyl-glutamic acid, a synthetic dipeptide made of lysine and glutamic acid, developed in St. Petersburg as one of Vladimir Khavinson's short-peptide bioregulators. Its developers describe it as a thymomimetic. Nearly all its evidence is rodent, cell and small Russian clinical studies from one research network, and no regulator has approved it.

No established human dose Details ↓

Overview

What is it?

Vilon belongs to a family of very short synthetic peptides developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. At two amino acids it is one of the smallest in that family. Its developers call it a thymomimetic, meaning a compound meant to reproduce the effects of thymus extracts, and most of its research concerns the immune system, tumours and ageing.

The animal work is broad but thin: fewer chemically induced tumours in mice and less vessel leakiness in rats with kidney failure. Each is a single study, and we found no independent replication of any of them.

The cell work is where the group's theory lives: loosened chromatin in lymphocytes from older people, more T-helper differentiation in thymus cultures, and changed SIRT1 and PARP expression in ageing stem cells, with modelling suggesting the dipeptide binds DNA in those genes' promoters. That direct peptide-to-DNA idea is the Khavinson group's central hypothesis and has not been established elsewhere.

Human data are two small Russian reports in type 1 diabetes, where adding vilon to standard care improved clotting markers and sometimes lowered insulin needs. Neither describes randomisation. Vilon is a laboratory compound with a single-source literature, not a treatment.

Lys-Glu
Its two amino acids
the KE dipeptide
8.2×
SIRT1 protein in stem cells
young mesenchymal stem cells, in culture · PMID 37782636
Science

Mechanism of Action

Vilon is the dipeptide Lys-Glu (KE), one of the very short synthetic peptides developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology.

🧬

Chromatin and genes

In lymphocytes from older people it unrolled facultative heterochromatin and reactivated ribosomal genes, and in mouse hearts it changed the expression of 36 of 15,247 measured gene clones more than twofold.

🛡️

Thymus cells

In human and rat thymic cells it raised the differentiation marker CD5 and pushed T-cell precursors toward CD4 helper cells.

🔬

Stem-cell ageing markers

In young mesenchymal stem cells it raised SIRT1 gene expression 6-fold and SIRT1 protein 8.2-fold.

🐭

Tumours in animals: mixed

It cut chemically induced bladder tumours in rats, 56% against 75.5% of controls, but gave no protection in breast-cancer-prone mice.

Evidence

Published Research

These are the studies of vilon, read from their PubMed abstracts: 13 in animals, 6 in cells or tissue cultures and 2 in people. One mouse study found more tumours with vilon rather than fewer.

Animal2005

Chemically induced tumours in mice

In mice given 1,2-dimethylhydrazine, tumours developed in 14.3% of animals treated with vilon at 10 micrograms per kg that survived to first tumour detection, against 60% of controls; pre-cancerous kidney changes were also reduced.

PMID: 16308980
Animal2005

Chronic kidney failure in rats

Subcutaneous vilon lowered serum TGF-beta1 and the permeability of mesenteric microvessels two months after chronic renal failure began.

PMID: 16142267
Animal2003

With cyclophosphamide in mice

Vilon at 1 mg per kg increased survival of mice with Lewis lung carcinoma, but given together with cyclophosphamide it decreased survival.

PMID: 14743610
In Vitro2004

Chromatin in lymphocytes from older people

Vilon unrolled facultative heterochromatin and reactivated ribosomal genes in cultured lymphocytes from older people.

PMID: 15105581
In Vitro2013

Thymus cell cultures

The dipeptide raised the differentiation marker CD5 in human and rat thymic cells and pushed T-cell precursors toward CD4 helpers; an analogue had the stronger effect.

PMID: 23486604
In Vitro2023

SIRT1 and PARP in ageing stem cells

KE peptide raised SIRT1 gene expression and protein 6-fold and 8.2-fold in young mesenchymal stem cells and lowered PARP1 and PARP2 during ageing; modelling proposed binding to GCGG and GGGC DNA sequences in their promoters.

PMID: 37782636
Human2006

Coagulation in type 1 diabetes

In type 1 diabetes with chronic intravascular coagulation, adding vilon reduced or abolished it, less so in older patients with severe disease.

PMID: 17152731
Human2007

Immune status and hemostasis in diabetes

Added to standard therapy in older patients with type 1 diabetes, vilon raised antithrombin III and protein C, stimulated fibrinolysis, normalised several immune cell counts, and in most cases lowered the insulin dose needed.

PMID: 18306698
Animal2000

Lifespan and ageing in mice

Given to female CBA mice from the sixth month of life, vilon increased physical activity and endurance, lowered body temperature, prolonged lifespan and prevented spontaneous tumours, with no effect on the age-related decline of oestrous function or on free-radical processes and no harm to development.

PMID: 11140587
Animal2001

Chemically induced bladder tumours in rats

In rats given a bladder carcinogen, tumours developed in 56% of vilon-treated animals against 75.5% of controls, and vilon halved the incidence of preneoplastic and early neoplastic changes in the bladder lining.

PMID: 11586406
Animal2002

Breast-cancer-prone mice: no protection

In HER-2/neu transgenic mice, monthly vilon courses did not inhibit breast tumours as epitalon did: 95% of vilon-treated mice developed two or more tumours, against 75% of controls and 56% on epitalon, and lung metastases were 2.6 times as frequent with vilon as with epitalon, though the share of mice with any metastasis was about the same in all three groups.

PMID: 12101568
Animal2001

Recovery of radiation-sensitive organs

In rats given a single whole-body dose of gamma radiation, vilon stimulated thymocyte proliferation and the proliferative potential of intestinal stem cells, which the authors read as faster recovery of these organs; epitalon instead slowed duodenal metabolism and suppressed blood-cell formation in the spleen.

PMID: 11427924
Animal2005

Repeated low-dose radiation and mercury

In rats repeatedly exposed to mercury and low-dose gamma radiation, vilon brought lymphocyte counts back to normal by day 30, unlike in exposed untreated rats, and reduced illness over the following 15 months.

PMID: 16075682
Animal2002

Emotional stress in rats

In male rats, injected vilon raised resistance to emotional stress in open-field tests, prevented adrenal enlargement and thymus shrinkage, raised blood albumin and lowered stress-related Fos activation in the paraventricular hypothalamus, most in stress-resistant animals.

PMID: 12587272
Animal2001

Digestive enzymes in ageing rats

Given by mouth to rats aged 3 and 11 months, vilon raised the activity of digestive enzymes (invertase, maltase, alkaline phosphatase, amino- and dipeptidases) along the gut, most in the older animals, which narrowed the difference between the two ages.

PMID: 11586413
Animal2000

Cirrhotic rat liver: a weak effect

In rats with liver cirrhosis from long-term carbon tetrachloride poisoning, five days of vilon restored glucose-6-phosphatase activity and had a weak effect on regeneration: liver-cell protein content and ploidy were 4.7% and 11.5% higher than in untreated cirrhotic rats.

PMID: 11033862
Animal2006

Hormones and sexual function in old male rats

In old male rats with one testis removed, a model of age-related decline, regular vilon activated sexual function and changed LH, prolactin, ACTH and hypothalamic neurotransmitters; the authors highlight a significant fall in blood prolactin.

PMID: 17152729
Animal2002

Gene expression in the mouse heart

Of 15,247 gene clones measured by microarray in the hearts of mice, vilon alone changed the expression of 36 more than two-fold, against 98 for epitalon and 144 for the two combined.

PMID: 12360356
In Vitro2004

Human thymus cells in culture

In cultured human thymocytes and thymic epithelial cells, vilon increased nucleolar organiser proteins that drive ribosome production, while epitalon reduced them, and vilon had a direct mitogenic effect, turning thymocytes into proliferating blast cells.

PMID: 15455093
In Vitro2020

Ageing human thymus cells

In human thymus cell cultures undergoing replicative ageing, the KE peptide (vilon) increased the area of mitochondrial staining 1.5-fold and lowered expression of the ribosomal protein L7A by 15%, changes the authors read as normalising mitochondrial and ribosomal function.

PMID: 33342107
In Vitro2002

Spleen tissue from young and old rats

Added to cultured spleen explants from rats aged 3 days, 3 weeks and 2 years, vilon kept the tissue structurally stable and activated regeneration and cell function, with the strongest effect in explants from old rats.

PMID: 12096432
Dosing

No Established Human Dose

Vilon has been given to people in only two small studies of type 1 diabetes, as an addition to standard therapy, where the authors report less intravascular clotting and better levels of natural anticoagulants; neither abstract states how much was given. The rest of its evidence comes from cells, rats and mice.

What this rests on: PMID 17152731, PMID 18306698.

Educational information, not medical advice. The doses on this page come from approved labels, published studies and, where no study exists, amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

For Buyers

What a Buyer Needs to Know

What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.

What is sold

Unknown: we hold no label and no published test that says what forms or vial sizes Vilon is sold in. A vial's own label is a seller's claim, not a source.

Mixing a vial: a worked example

Unknown: no human dose of Vilon has been established (see No Established Human Dose below), so there is no amount to work out. The reconstitution calculator does the arithmetic for any vial, water and dose.

Storage before and after mixing

Unknown: no label or published stability study on file says how to store Vilon, before or after mixing. The mixing guide sets out the general rules, with their sources: keep a mixed vial in the fridge, and use it promptly, as the bacteriostatic water label says of any drug dissolved in it. The 28 days often quoted is the limit for an opened multiple-dose vial from a manufacturer, an outer limit set for sterility, not a time a mixed solution has been shown to keep. Nobody has published how long Vilon stays intact once mixed.

How it is taken

Unknown: with no established human dose, there is no established way of taking Vilon. What the human studies gave and how is set out under No Established Human Dose.

What to expect, and when

Unknown: no cited half-life and no label or trial duration on this page says how long Vilon lasts or how long it was given. Results reported in the studies are under Published Research.

Side effects, and when to stop or get help

From the Side Effects section: No adverse events are described in the abstracts above; No controlled safety study was found. Full list and cautions ↓

When to stop or get help: unknown; no label or trial on file sets rules for stopping Vilon. Treat a severe or unexpected reaction as a reason to stop and see a doctor.

Source: the Side Effects section below (“The abstracts read report no adverse effects, which is not the same as showing safety”).

Interactions

Unknown: a PubMed search for human interaction studies of Vilon (reviewed 2026-10-03) found none. Unknown is not the same as safe to combine.

Every peptide's record, with its source: the interaction matrix.

Checking what you bought

Unknown: no published independent test of Vilon products is in our lab-results database yet, so how products sold under this name measure up is not known.

To read a certificate of analysis, paste it into the COA decoder; it checks the measured mass against Vilon's expected mass, 275.3 Da, from this entry's molecular data. Trust & Verification explains what independent testing can and cannot show.

Legal status

US: Research Chemical (No approval found: openFDA's Drugs@FDA index returns no record for vilon (searched October 3, 2026)). Sport: Prohibited (S0 catch-all).

Country by country ↓ · Regulatory tracker

Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.

Safety

Side Effects & Contraindications

Reported Side Effects

The abstracts read report no adverse effects, which is not the same as showing safety.

● No adverse events are described in the abstracts above
● No controlled safety study was found

Contraindications & Cautions

There is no label.

● Not approved for any use; no regulator-reviewed safety information exists
Questions

Frequently Asked Questions

?What is vilon?

A synthetic dipeptide, lysine joined to glutamic acid (Lys-Glu), from Vladimir Khavinson's series of short-peptide bioregulators. Its developers describe it as a thymomimetic.

?Is there good evidence that vilon works?

No. The literature is mostly single rodent and cell studies from one network of Russian institutes, plus two small Russian clinical reports in diabetes that do not describe randomisation. Nothing has been independently replicated in what we read.

?How is vilon related to thymogen and thymalin?

All three come from the same research programme. Thymalin is a thymus extract, thymogen is the dipeptide Glu-Trp, and vilon is the dipeptide Lys-Glu; vilon is described by its developers as a thymomimetic.

Bibliography

References

  1. [other] PubChem CID 7010502, Lysylglutamic acid (synonyms include Vilon, Lys-Glu and AB-0 peptide): formula C11H21N3O5, molecular weight 275.30. Read October 3, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/7010502
  2. [fda] FDA. Drugs@FDA (openFDA): no application on record for vilon. Read October 3, 2026.
  3. [pubmed] Pliss GB, et al. "[The effect of vilon (Lys-Glu) on 1.2-dimethylhydrazine-induced neoplasia]." Vopr Onkol, 2005;51(4):466-9. PMID: 16308980.
  4. [pubmed] Gavrisheva NA, et al. "Effect of peptide Vilon on the content of transforming growth factor-beta and permeability of microvessels during experimental chronic renal failure." Bull Exp Biol Med, 2005;139(1):24-6. PMID: 16142267.
  5. [pubmed] Lezhava T, et al. "Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people." Biogerontology, 2004;5(2):73-9. PMID: 15105581.
  6. [pubmed] Sevostianova NN, et al. "Immunomodulating effects of Vilon and its analogue in the culture of human and animal thymus cells." Bull Exp Biol Med, 2013;154(4):562-5. PMID: 23486604.
  7. [pubmed] Khavinson VK, et al. "[KE peptide regulates SIRT1, PARP1, PARP2 gene expression and protein synthesis in human mesenchymal stem cells aging.]." Adv Gerontol, 2023;36(3):302-312. PMID: 37782636.
  8. [pubmed] Kuznik BI, et al. "[Effect of thymomimetic vilon on blood coagulation system and fibrinolisis in diabetes mellitus type 1 patients of different age]." Adv Gerontol, 2006;19:107-15. PMID: 17152731.
  9. [pubmed] Kuznik BI, et al. "[Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus]." Adv Gerontol, 2007;20(2):106-15. PMID: 18306698.
  10. [pubmed] Barykina OP, et al. "[Combined effect of vilon and cyclophosphane on tumor transplants and lymphoid tissue explants in mice and rats of various age]." Adv Gerontol, 2003;12:128-31. PMID: 14743610.
  11. [pubmed] Khavinson VK, et al. "Effect of vilon on biological age and lifespan in mice." Bull Exp Biol Med, 2000;130(7):687-90. PMID: 11140587.
  12. [pubmed] Pliss GB, et al. "Inhibitory effect of peptide vilon on the development of induced rat urinary bladder tumors in rats." Bull Exp Biol Med, 2001;131(6):558-60. PMID: 11586406.
  13. [pubmed] Alimova IN, et al. "[Effect of Epitalon and Vilon treatment on mammary carcinogenesis in transgenic erbB-2/NEU mice]." Vopr Onkol, 2002;48(1):57-60. PMID: 12101568.
  14. [pubmed] Khavinson VK, et al. "Immunohistochemical and morphometric analysis of effects of vilon and epithalon on functional morphology of radiosensitive organs." Bull Exp Biol Med, 2001;131(3):285-92. PMID: 11427924.
  15. [pubmed] Ivanov SD, et al. "[Vilon effect on consequences of repeated radioactive and mercuric impact in small doses]." Adv Gerontol, 2005;16:88-91. PMID: 16075682.
  16. [pubmed] Koplik EV, et al. "[Effect of dipeptide vilon on emotional stress resistance in rats]." Ross Fiziol Zh Im I M Sechenova, 2002;88(11):1440-52. PMID: 12587272.
  17. [pubmed] Khavinson VK, et al. "Effect of the dipeptide vilon on activity of digestive enzyme in rats of various ages." Bull Exp Biol Med, 2001;131(6):583-5. PMID: 11586413.
  18. [pubmed] Kudriavtseva MV, et al. "[Effect of "vilon" on cirrhotically changed rat liver. Liver regeneration, and status of glycogen-forming function of hepatocytes]." Tsitologiia, 2000;42(8):758-64. PMID: 11033862.
  19. [pubmed] Kudriavtseva TA, et al. "[Effect of vilon on neuroendocrine status and sexual function of old male rats]." Adv Gerontol, 2006;19:97-101. PMID: 17152729.
  20. [pubmed] Anisimov SV, et al. "Studies of the effects of Vilon and Epithalon on gene expression in mouse heart using DNA-microarray technology." Bull Exp Biol Med, 2002;133(3):293-9. PMID: 12360356.
  21. [pubmed] Raikhlin NT, et al. "Expression of argyrophilic proteins in the nucleolar organizer regions of human thymocytes and thymic epitheliocytes under conditions of coculturing with vilon and epithalon peptides." Bull Exp Biol Med, 2004;137(6):588-91. PMID: 15455093.
  22. [pubmed] Ivko OM, et al. "[The influence of AEDG and KE peptides on mitochondries stain and L7A ribosomes protein expression during human pineal gland and thymus cell senescence in vitro.]." Adv Gerontol, 2020;33(4):741-747. PMID: 33342107.
  23. [pubmed] Kniaz'kin IV, et al. "[Functional morphology of organotypic culture of spleens from rats of various ages exposed to vilon]." Adv Gerontol, 2002;9:110-5. PMID: 12096432.
  24. [pubmed] Khavinson VKh, et al. "A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice." Dokl Biol Sci, 2000;372:261-3. PMID: 10944717.
  25. [pubmed] Pliss GB, et al. "[Effect of vilon and epithalone on induction and growth of induced bladder neoplasms in rats]." Vopr Onkol, 2001;47(5):601-7. PMID: 11785104.
  26. [pubmed] Kniaz'kin IV, et al. "[The effect of vilon on the thymus and spleen in a radiation model of premature aging]." Adv Gerontol, 2002;9:105-9. PMID: 12096431.
  27. [pubmed] Khavinson VKh, et al. "Effect of Vilon and Epithalon on glucose and glycine absorption in various regions of small intestine in aged rats." Bull Exp Biol Med, 2002;133(5):494-6. PMID: 12420071.
  28. [pubmed] Khavinson VKh, et al. "Effect of vilon and epithalon on activity of enzymes in epithelial and subepithelial layers in small intestine of old rats." Bull Exp Biol Med, 2002;134(6):562-4. PMID: 12660839.
  29. [pubmed] Bykov NM, et al. "[Characteristics of effect of ultralow doses of vilon in organotypic culture of spleens from rats of various ages]." Adv Gerontol, 2002;10:85-7. PMID: 12577696.
  30. [pubmed] Bykov NM, et al. "[Reciprocal relation of proliferative activity in central and peripheral zones of splenic organ culture exposed to vilon in rats of various ages]." Adv Gerontol, 2003;11:104-8. PMID: 12820529.

Sources & Citations

Studies were read from their PubMed records, October 3, 2026. Several are Russian-language articles read from their English abstracts.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.

Last reviewed: 2026-10-19